Publication
Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis
| dc.contributor.author | Nagia, L | |
| dc.contributor.author | Lemos, J | |
| dc.contributor.author | Abusamra, K | |
| dc.contributor.author | Cornblath, WT | |
| dc.contributor.author | Eggenberger, ER | |
| dc.date.accessioned | 2018-07-02T17:11:09Z | |
| dc.date.available | 2018-07-02T17:11:09Z | |
| dc.date.issued | 2015-07 | |
| dc.description.abstract | PURPOSE: To calculate the rate and timing of conversion from ocular myasthenia gravis to generalized myasthenia gravis. DESIGN: Retrospective multicenter analysis. SUBJECTS: Patients included in the study were diagnosed with ocular myasthenia gravis without the presence of generalized disease at onset. METHODS: We conducted a retrospective multicenter analysis. We reviewed charts of 158 patients who met diagnostic criteria for ocular myasthenia gravis. Patients were divided into 2 subgroups: an immunosuppressant treatment group and a nonimmunosuppressant treatment group. Timing of conversion to generalized disease and duration of follow-up also was evaluated. Additional data such as clinical symptoms at presentation, laboratory test results, and chest imaging results also were recorded. MAIN OUTCOME MEASURES: Conversion rates to generalized myasthenia at 2 years, effect of immunosuppression on conversion, and timing of conversion. RESULTS: The 158-patient cohort included 76 patients who received immunosuppressant therapy; the remaining 82 patients did not. The overall conversion rate to generalized disease was 20.9%. At 2 years, generalized myasthenia developed in 8 of 76 patients in the treated group and in 15 of 82 patients in the nonimmunotherapy group (odds ratio, 0.52; 95% confidence interval, 0.20-1.32). Median time for conversion to generalized disease was 20 months in the nonimmunosuppressant group and 24 months in the immunosuppressant group. Conversion occurred after 2 years of symptom onset in 30% of patients. CONCLUSIONS: Conversion rates from ocular to generalized myasthenia gravis may be lower than previously reported both in immunosuppressed and nonimmunosuppressed patients. A subset of patients may continue to convert to generalized disease beyond 2 years from onset of symptoms, and close monitoring should be continued. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Ophthalmology. 2015 Jul;122(7):1517-21. | pt_PT |
| dc.identifier.doi | 10.1016/j.ophtha.2015.03.010 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.4/2154 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.subject | Miastenia Gravis | pt_PT |
| dc.title | Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 1521 | pt_PT |
| oaire.citation.issue | 7 | pt_PT |
| oaire.citation.startPage | 1517-21 | pt_PT |
| oaire.citation.volume | 122 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |